The effect of desmopressin on blood loss in patients with rheumatoid arthritis undergoing hip arthroplasty

What Was Tested

Researchers studied Vasopressin and Desmopressin in the context of rheumatoid arthritis in this randomized controlled trial publication.

Blood loss is an important issue for patients with rheumatoid arthritis undergoing hip surgery.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Secondary endpoints included red cell transfusion requirements and haemoglobin.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

As a double-blind Vasopressin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vasopressin group a baseline to be compared against.

The primary endpoint was the total blood loss measured till the end of the fourth post-operative day.

What Was Measured

PubMed files the paper under topics including Arthritis, Rheumatoid, Arthroplasty, Replacement, Hip, Blood Loss, Surgical, Deamino Arginine Vasopressin, Endpoint Determination, Erythrocyte Transfusion and Hemoglobins.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin in people with rheumatoid arthritis.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Acta anaesthesiologica Scandinavica), a journal based in England.

More context: the Vasopressin compound page and the Desmopressin compound page, Rheumatoid arthritis research.